Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED (4568)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2011 | 10:20am CEST
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)

Reference

Date of Board of Directors resolution: June 27, 2011

###
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
06/23DAIICHI SANKYO : The potential of antibody drug conjugates in the treatment of c..
AQ
06/21DAIICHI SANKYO : Findings from Daiichi Sankyo in the Area of Opioids Described (..
AQ
06/21DAIICHI SANKYO : Findings on Staphylococcus aureus Detailed by Investigators at ..
AQ
06/21DAIICHI SANKYO : Announces Disposal of Treasury Shares as Restricted Share-Based..
AQ
06/20DAIICHI SANKYO : Launches FENTANYL CITRATE TAPE for 1day 'DAIICHI SANKYO' in Jap..
AQ
06/18DAIICHI SANKYO : Announces Disposal of Treasury Shares as Restricted Share-Based..
PU
06/18DAIICHI SANKYO : Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Qui..
PU
06/14DAIICHI SANKYO : "Method for Producing Dicarboxylic Acid Compound" in Patent App..
AQ
06/14DAIICHI SANKYO : to Present Late-Breaking Phase 3 Data for Single Agent Quizarti..
AQ
06/07DAIICHI SANKYO : Initiates Phase 2 Study of DS-8201 in Patients with Advanced HE..
AQ
More news
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/08EC OKs AstraZeneca's Tagrisso for first-line lung cancer 
06/08Key events next week - healthcare 
06/06Claimant threshold met in $358M Daiichi Sankyo product liability settlement 
06/04Daiichi Sankyo (DSNKY) Presents At 2018 American Society Of Clinical Oncology.. 
Financials ( JPY)
Sales 2019 912 B
EBIT 2019 75 000 M
Net income 2019 57 636 M
Finance 2019 375 B
Yield 2019 1,62%
P/E ratio 2019 47,86
P/E ratio 2020 44,21
EV / Sales 2019 2,94x
EV / Sales 2020 2,89x
Capitalization 3 059 B
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 3 773  JPY
Spread / Average Target -13%
EPS Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Sunao Manabe Representative Director, EVP & GM-Personnel
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED44.05%27 807
JOHNSON & JOHNSON-12.08%329 475
PFIZER0.80%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-10.81%191 785
MERCK AND COMPANY9.24%165 373